As an institute specializing in the professional and accurate clinical and non-clinical trials, KBI evaluates the effectiveness and safety of pharmaceuticals, medical devices, functional food, and cosmetics. KBI performs human skin study and official medical device test hospital study based on responsibilities of dermatologists, plastic surgeons, pediatricians, endocrinologists, anesthesiologists, and dentists. KBI is also in charge of approval and accreditation of KFDA, FDA, CE/MDR, etc. It also collects test subjects quickly based on optimal test design and provides fast, objective, and precise test report based on systematic management of compliance and abnormal reaction.
We are now in an era where development is led by companies, but validation and regulatory approval must be entrusted to specialized institutions.
Today¡¯s consumers meticulously examine every ingredient and every review.
They choose products backed by solid scientific evidence.
This goes beyond marketing Reliable data, supported by verifiable clinical and non-clinical results, is now essential.
At KBI (Korea Biomedical Research Institute),
we are a global R&D outsourcing partner equipped with
expertise in regulatory strategies and hands-on testing capabilities
tailored to not only Korean MFDS approvals, but also FDA, CE/MDR compliance worldwide.
We don¡¯t just offer testing services.
We directly perform clinical, ex vivo, and preclinical studies,
and participate in product design from the earliest development stages.
KBI is not just a testing lab
We are your strategic research partner,
providing:
• Scientifically structured efficacy data
• Highly credible study results
• Enhanced recognition in both academic and commercial markets
Let your team focus on innovation,
and entrust the validation, regulatory approvals, and credibility building
to KBI – your expert research institution.
• PI of KBI
• Deputy Director of Kyung Hee Center for Digital Health
• Medicine Assistant Professor of College of Medicine, Kyung Hee University
• Last 3 years Published paper: 36 papers with IF 10 points¡è
- The Lancet, 2022, 400(10347), 185-235: IF 202.731
- The Lancet, 2021, 398(10299), 503-521: IF 202.731
- The Lancet Psychiatry, 2021, 8(4), 271-272: IF 77.056
- The Lancet Psychiatry, 2021, 7(12), 1025-1031: IF 77.056
- The Lancet infectious diseases, 2022, 22(11), 1626-1647: IF 46.750
• Editor of 4 SCI journals: Plos One, BMC Pediatrics, BMC Pulmonary Medicine, World Journal of Pediatrics
• First Asian Fellow American Academy of Allergy Asthma and Immunology & Fellow American College of Allergy Asthma and Immunology(FAAAAI & FACAAI)
• First Korean Mentor of European Academy of Allergy and Clinical Immunology(EAACI)
• Ranked 1st in the field of medicine for those who shiine Korea for 3 years (Theory)
• Ranked 1st in the field of medicine fo COVID-19 research in Korea (Hanbitsa)
• First Asian Rising Star Award, Young Medical Scientist Award (Clinical and Allergy) of American Thoracic Society
Under the supervision of medical and dermatological experts, KBI specializes in human application trials for skin related drugs, medical devices, health functional foods and cosmetics. With years of experience in skin clinical trials and dermatological research, KBI has a deep understanding of client needs and challenges. Additionally, by offering a wide range of testing options, KBI guarantees professionalism and accuracy while providing transparent and objective clinical trial data.
(13201) °æ±âµµ ¼º³²½Ã Áß¿ø±¸ »ç±â¸·°ñ·Î 99 (»ó´ë¿øµ¿)
¼¾Æ®·²ºñÁö 2Â÷ Bµ¿ 10Ãþ 1002È£~1005È£
(13201) 1002~1005, 10F, 99, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea